The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies. (Q47978690)

7 February 2018

review article

1 reference

title

The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies. (English)

1 reference

7 February 2018

1 reference

Denny WA

1

1 reference

7 February 2018

Wilson WR

series ordinal

2

1 reference

7 February 2018

publication date

1 April 1998

1 reference

7 February 2018

Journal of Pharmacy and Pharmacology

published in

1 reference

7 February 2018

volume

50

1 reference

7 February 2018

issue

4

1 reference

7 February 2018

page(s)

387-394

1 reference

7 February 2018

The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--I. Purification and properties of a nitroreductase enzyme from Escherichia coli--a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT).

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1998.TB06878.X

Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1998.TB06878.X

Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1998.TB06878.X

The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1998.TB06878.X

The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1998.TB06878.X

2,4-dinitro-5-ethyleneiminobenzamide (CB 1954): a potent and selective inhibitor of the growth of the Walker carcinoma 256.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1998.TB06878.X

Hypoxia in tumors: a paradigm for the approach to biochemical and physiologic heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1998.TB06878.X

Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1998.TB06878.X

Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1998.TB06878.X

Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1998.TB06878.X

A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1998.TB06878.X

An experimental and mathematical model for the extravascular transport of a DNA intercalator in tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1998.TB06878.X

Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1998.TB06878.X

Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1998.TB06878.X

Preparation and characterization of a .beta.-lactamase-Fab' conjugate for the site-specific activation of oncolytic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1998.TB06878.X

Designed enediynes: a new class of DNA-cleaving molecules with potent and selective anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1998.TB06878.X

Chemistry and biology of natural and designed enediynes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1998.TB06878.X

Transcriptional Regulatory Sequences of Carcinoembryonic Antigen: Identification and Use with Cytosine Deaminase for Tumor-Specific Gene Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1998.TB06878.X

Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1998.TB06878.X

Vectors for cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1998.TB06878.X

Virtual cofactors for an Escherichia coli nitroreductase enzyme: Relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1998.TB06878.X

10.1111/J.2042-7158.1998.TB06878.X

21 January 2018

Identifiers

DOI

1 reference

7 February 2018

release_j6dpq33zbrfwzk6aazag3i2mde

Fatcat ID

0 references

PubMed ID

9625483

1 reference

7 February 2018